TG4050 is an individualized MVA-based immunotherapy designed to stimulate and educate the immune system of patients to recognize and destroy tumor cells.
TG4050 is indicated for ovarian cancer patients who have already received first-line treatment.
TG4050 is designed to target a panel of patient-specific mutations selected using NEC's Neoantigen Prediction System.
TG4050 will be administered in the Phase 1 Clinical Trial as subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
Clinical Trial NCT03839524: A Trial Evaluating TG4050 in Ovarian Carcinoma
- This is a multicenter, open-label, single-arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.